This story has been updated from a previous version.
 
NEW YORK, June 11 - Affymetrix said Monday it was reducing its second quarter revenue forecast to between $44 million and $50 million, down from a previously expected $56 million, citing lower than expected orders of GeneChips and a drop in the demand for spotted array instrumentation.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.